CJC-1295 and Ipamorelin: The Research Case for GHRH/GHRP …

CJC-1295 and Ipamorelin: The Research Case for GHRH/GHRP Combination in GH Studies

The combination of a GHRH analogue and a GHRP creates a synergistic GH secretagogue profile that neither compound achieves alone. We examine the mechanistic rationale and what preclinical combination data shows for CJC-1295 and Ipamorelin.

28 juin 202610 min read

6–8 days

CJC-1295 DAC Half-Life

2×

Synergistic GH vs Either Alone

GHRH-R + GHS-R1a

Dual Receptor Activation

No Cortisol

Ipamorelin Selectivity Advantage

Two Receptors, One Synergistic Signal

Growth hormone secretion from the pituitary is controlled by two opposing hypothalamic signals: GHRH (growth hormone-releasing hormone), which stimulates GH release via the GHRH receptor, and somatostatin, which inhibits it. GHRPs (growth hormone-releasing peptides) like Ipamorelin work through a completely separate receptor — the ghrelin receptor (GHS-R1a) — to stimulate GH release and simultaneously suppress somatostatin tone.

The combination of CJC-1295 (a GHRH analogue) and Ipamorelin (a GHRP) targets both arms of this system simultaneously. The two compounds not only add their individual GH-stimulating effects — they produce synergistic amplification, with peak GH concentrations exceeding additive predictions. This dual-pathway convergence is the mechanistic foundation for the CJC-1295/Ipamorelin blend.

CJC-1295: Solving the GHRH Half-Life Problem

DPP-4 Resistance

Native GHRH degrades within 7 minutes via DPP-4 cleavage. CJC-1295's amino acid substitutions block DPP-4 recognition, preventing rapid plasma degradation.

Albumin Binding (DAC)

The DAC (Drug Affinity Complex) maleimide chemistry allows CJC-1295 to covalently bind circulating albumin — dramatically extending half-life to 6–8 days.

Sustained GH Elevation

The long half-life of CJC-1295 with DAC produces continuous GHRH receptor stimulation and sustained IGF-1 elevation — distinct from the pulsatile pattern of Mod GRF 1-29 (no DAC).

GHRH Receptor Agonism

Despite structural modifications, CJC-1295 retains full agonist activity at the GHRH receptor with potency comparable to native GHRH in receptor binding assays.

Ipamorelin: The Selective GHRP

Ipamorelin is a pentapeptide GHRP that occupies the GHS-R1a (ghrelin receptor) with high selectivity. Its selectivity profile is what distinguishes it from earlier GHRPs: while compounds like GHRP-6 and GHRP-2 stimulate GH release alongside significant prolactin and cortisol secretion, Ipamorelin produces robust GH stimulation with minimal or absent cortisol and prolactin effects in rodent and non-human primate models.

This selectivity makes Ipamorelin the preferred GHRP for combination research — the cortisol and prolactin confounders that complicate interpretation of older GHRPs are largely absent, allowing researchers to study GH/IGF-1 axis effects with cleaner endpoints.

Compound	Receptor	GH Effect	Cortisol/Prolactin
CJC-1295	GHRH-R	Strong, sustained	Not stimulated
Ipamorelin	GHS-R1a	Strong, pulsatile	Minimal (selective)
CJC + Ipa (blend)	Both	Synergistic (×2)	Minimal
GHRP-6 (comparison)	GHS-R1a	Strong, pulsatile	Significant stimulation
Native GHRH (ref)	GHRH-R	Rapid, 7-min t½	Not stimulated

Research Note

The synergistic GH response from CJC-1295 + Ipamorelin combination reflects genuine dual-pathway biology. GHRH-R signalling (cAMP/PKA) and GHS-R1a signalling (PLC/IP3/Ca²⁺) are pharmacologically independent routes to GH secretion that converge on the same secretory endpoint — making the combination uniquely suited for studying GH axis pharmacology.

Composé de recherche · Usage scientifique uniquement

CJC-1295 + Ipamorelin Blend

GHRH analogue + GHRP · ≥99% HPLC purity · Pre-blended

GHRH/GHRP dual pathway
Synergistic GH release
Selective cortisol profile

Voir le composé de recherche

≥99% PuretéCertifié HPLCLivraison EURecherche uniquement

Research Applications of the Combination

The preblended CJC-1295/Ipamorelin formulation is primarily useful for researchers studying: GH secretagogue pharmacology (GHRH/GHRP receptor characterisation), IGF-1 pathway downstream effects (protein synthesis, cell proliferation, fat metabolism), GH pulse architecture research (comparing pulsatile vs sustained GH stimulation), and the somatostatin system (Ipamorelin's simultaneous somatostatin suppression is a distinct research tool).

Research Use Only

CJC-1295 and Ipamorelin are research compounds for in vitro and preclinical laboratory use only. Neither has an approved human therapeutic application. Not for human administration.

Frequently Asked Questions

What is the difference between CJC-1295 and native GHRH?

Native GHRH (growth hormone-releasing hormone) has a plasma half-life of approximately 7 minutes due to rapid degradation by DPP-4 (dipeptidyl peptidase-4) and other plasma endopeptidases. CJC-1295 (also known as DAC:GRF, drug affinity complex GHRH) addresses this limitation through two modifications: first, amino acid substitutions that prevent DPP-4 cleavage; and second, a C-terminal DAC (Drug Affinity Complex) that covalently binds to circulating albumin. Albumin binding extends CJC-1295's half-life to approximately 6-8 days, compared to minutes for native GHRH, while retaining GHRH receptor agonism.

How does Ipamorelin complement CJC-1295 mechanistically?

CJC-1295 acts on the GHRH receptor (GHRH-R) on pituitary somatotrophs, stimulating GH synthesis and release through the cAMP/PKA pathway. Ipamorelin acts on a different receptor — ghrelin receptor (GHS-R1a) — which uses a distinct intracellular signalling cascade involving phospholipase C, IP3, and calcium mobilisation. The two pathways converge on GH secretion but through independent routes, and combining them produces approximately twice the GH release compared to either compound alone in rodent and in vitro studies. Ipamorelin also selectively spares prolactin and cortisol secretion, distinguishing it from older GHRPs.

What does the preclinical combination data show for CJC-1295 plus Ipamorelin?

Preclinical combination studies in rodents and primates demonstrate synergistic GH pulse amplification — peak GH concentrations after combined administration exceed additive predictions from single-compound studies. This synergy is consistent with the dual-pathway convergence mechanism. Secondary endpoints including IGF-1 elevation (sustained over 24–48 hours with the long-acting CJC-1295 DAC form), nitrogen retention, and lean body mass preservation in animal models have been reported. Whether the combination's GH effect translates equivalently to all these secondary endpoints in humans requires clinical data not yet available.

What is the difference between CJC-1295 with and without DAC?

CJC-1295 with DAC (Drug Affinity Complex) covalently binds to albumin via a maleimide linker, extending half-life to 6-8 days. CJC-1295 without DAC (also called Mod GRF 1-29) retains the amino acid substitutions that prevent DPP-4 degradation but lacks the albumin-binding chemistry, resulting in a half-life of approximately 30-60 minutes. Mod GRF 1-29 produces more pulsatile GH release patterns similar to endogenous GHRH biology; CJC-1295 with DAC produces more sustained GH elevation. For research purposes, the two forms allow study of pulsatile vs continuous GHRH receptor stimulation and their different downstream effects.

Is the CJC-1295/Ipamorelin blend available for laboratory research?

Yes. The CJC-1295 (no DAC) + Ipamorelin combination is available as a research-grade blended formulation for in vitro and preclinical laboratory research. Research applications include GH secretagogue pharmacology, GHRH receptor characterisation, GHS-R1a signalling studies, IGF-1 pathway research, and investigation of GHRH/GHRP combination synergy in cell culture or animal models. VeloxPeptide's blend contains both compounds at ≥99% HPLC purity with a certificate of analysis.